Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
Solid Tumor
DRUG: Oratopo
Determination of Maximum Tolerated Dose (MTD), dose limiting toxicities occuring in the first cycle of therapy, Day 1 through 21
Safety assessment using Adverse Events of Oratopo, Safety assessment using Adverse Events of Oratopo, Weekly, from randomization throughout the study for approximately 24 months|Pharmacokinetics of Oratopo, Plasma concentrations of Oratopo, At the end of Cycle 1 (each cycle is 21 days)
This is a multicenter, open-label, safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid tumor malignancies. In the treatment period groups of 3 to 6 subjects will receive a single dose of oral Oratopo will be administered and will be followed for toxicity. Dose escalation will continue until an MTD is reached, or nonlinear increases in exposure are confirmed, or a maximum dose of Oratopo is reached.